Physician profile
Brian Davis
NPI 1093404089
$449.36
in general payments reported to CMS, 2019-2025
11 companies · $449 in 2025
The $449 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $449.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $95.84 | 2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.77 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $57.23 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $50.40 | 2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $42.26 | 2025 | Zoryve |
| Lilly USA, LLC | $39.10 | 2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $30.93 | 2025 | Symbravo |
| Astrazeneca Pharmaceuticals LP | $19.43 | 2025 | Farxiga |
| Almatica Pharma LLC | $19.26 | 2025 | Loreev Xr |
| Bayer Healthcare Pharmaceuticals INC. | $16.26 | 2025 | |
| Merck Sharp & Dohme LLC | $13.88 | 2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.